APPLICATION
ANDA202102
TYPE
ANDA
ORIGINAL APPROVAL
2015-04-28
LATEST ACTION
2025-01-24
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription
Products
ARIPIPRAZOLEPrescription
ARIPIPRAZOLE 15MG · TABLET, ORALLY DISINTEGRATING · ORAL
ARIPIPRAZOLEPrescription
ARIPIPRAZOLE 10MG · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2025-01-24Labeling · Supplement 26 · standardAP
2025-01-13Labeling · Supplement 25 · standardAP
2021-02-01Labeling · Supplement 18 · standardAP
2020-02-05Labeling · Supplement 17 · standardAP
2020-02-04Labeling · Supplement 16 · standardAP
2017-03-29Labeling · Supplement 2 · standardAP
2017-03-29Labeling · Supplement 7 · standardAP
2017-03-29Labeling · Supplement 1 · standardAP
2017-03-29Labeling · Supplement 6 · standardAP
2017-03-29Labeling · Supplement 4 · standardAP
2016-08-18Labeling · Supplement 5 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.